Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.04M P/E - EPS this Y 68.30% Ern Qtrly Grth -
Income -46.28M Forward P/E -0.06 EPS next Y -15.00% 50D Avg Chg -88.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -95.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -99.00%
Recommedations 3.00 Quick Ratio 0.45 Shares Outstanding 14.46M 52W Low Chg 134.00%
Insider Own 1.71% ROA -111.78% Shares Float 12.75M Beta 1.48
Inst Own 23.54% ROE -375.64% Shares Shorted/Prior 586.60K/589.42K Price 0.07
Gross Margin - Profit Margin - Avg. Volume 648,749 Target Price 0.75
Oper. Margin - Earnings Date Aug 14 Volume 8,194,395 Change 0.00%
About 9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sensenig Bethany Chief Financial Offi.. Chief Financial Officer Apr 21 Sell 1.21 9,100 11,011 41,077 04/21/23
Temperato John Chief Executive Offi.. Chief Executive Officer Jul 06 Buy 0.2277 125,000 28,462 1,427,522 07/08/22
Sirgo Mark A Director Director Mar 03 Buy 0.5784 86,450 50,002 1,279,045 03/07/22
Temperato John Chief Executive Offi.. Chief Executive Officer Mar 03 Buy 0.5559 100,000 55,590 1,252,522 03/04/22
- - - Jun 25 Sell 1.32 17,150,781 22,639,031 8,565,974 06/25/21
Sirgo Mark A Director Director Sep 14 Buy 0.64 148,485 95,030 21,485 09/14/20